Literature DB >> 1774770

Purified NAD(P)H-quinone oxidoreductase enhances the mutagenicity of dinitropyrenes in vitro.

A K Hajos1, G W Winston.   

Abstract

The effect of highly purified rat liver cytosolic NAD(P)H-quinone oxidoreductase [EC 1.6.99.2] on the mutagenicity of 1,3- 1,6- and 1,8-dinitropyrene (DNP) was studied in the Ames Salmonella typhimurium mutagenicity assay. NAD(P)H-quinone oxidoreductase over the range of 0.02-0.8 micrograms/plate (38-1500) units increased up to threefold the mutagenicity of all three DNPs in S. typhimurium TA 98. In TA98NR, a strain deficient in "classical" nitro-reductase, the mutagenicity of 1,6- and 1,8-DNP was essentially unchanged, whereas that of 1,3-DNP was markedly reduced. NAD(P)H-quinone oxidoreductase enhanced the mutagenicity of 1,6- and 1,8-DNP to approximately equivalent extents in TA98NR and TA98. The mutagenicity of 1,3-DNP in TA98NR was potently enhanced by the addition of NAD(P)H-quinone oxidoreductase in a dose-responsive manner. In the presence of 0.8 micrograms NAD(P)H-quinone oxidoreductase, 1,3-DNP displayed a mutagenic response in TA98NR that was comparable to that obtained in TA98. NAD(P)H-quinone oxidoreductase was found to increase the mutagenicity of 1,6- but not 1,3- or 1,8-DNP to mutagenic intermediates in TA98/1,8-DNP6, a strain deficient in O-acetyltransferase activity. The results suggest that NAD(P)H-quinone oxidoreductase not only catalyzes reduction of the parent DNP but also that of partially reduced metabolites generated from that DNP. Such reductive metabolism may lead to increased formation of the penultimate mutagenic species.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1774770     DOI: 10.1002/jbt.2570060407

Source DB:  PubMed          Journal:  J Biochem Toxicol        ISSN: 0887-2082


  1 in total

1.  Association of the GSTP1 and NQO1 polymorphisms and head and neck squamous cell carcinoma risk.

Authors:  Chang Gun Cho; Seok Ki Lee; Soon-Yhul Nam; Moo-Song Lee; Sang-Wook Lee; Eun Kyung Choi; Heon Joo Park; Sang Yoon Kim
Journal:  J Korean Med Sci       Date:  2006-12       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.